Purisys has industry-leading expertise and capabilities to manufacture Schedule I psychedelic compounds for human pharmaceutical applications.
Our API CDMO offering effectively integrates end-to-end project management, process development services, analytical services, regulatory support, and cGMP manufacturing of custom psychedelic compounds to rapidly advance your API to the clinic.
In a young and rapidly developing marketplace, psychedelic drug innovators can benefit from our experience and proven track record of success.
Manufactured in FDA-inspected and DEA-licensed facilities, our psychedelic APIs and reference standards support companies in early to late-phase clinical development. While other CDMOs may only be able to provide non-GMP grades of material, Purisys can support our customers from pre-clinical to commercial and all stages in between.
We can also help you navigate the regulatory and logistical hurdles associated with global shipments and permits for psychedelic APIs.